一分钟看懂
这是一项关于卵巢癌的II 期研究，登记的药物或干预包括Ipatasertib；Cobimetinib；Trastuzumab Emtansine；Atezolizumab；Bevacizumab；Paclitaxel；Giredestrant；Abemaciclib；Inavolisib；Palbociclib；Letrozole；，当前状态为研究进行中，已停止招募。登记地点显示中国San Francisco、St Louis、Charlotte、Columbus等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Ipatasertib；Cobimetinib；Trastuzumab Emtansine；Atezolizumab；Bevacizumab；Paclitaxel；Giredestrant；Abemaciclib；Inavolisib；Palbociclib；Letrozole；Olaparib；Luteinizing Hormone-Releasing Hormone (LHRH) Agonists；Cyclophosphamide · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- UCSF Helen Diller Family CCC · San Francisco
- Washington University School of Medicine · St Louis
- Levine Cancer Institute · Charlotte
- Ohio State University · Columbus
- University of Oklahoma Health Sciences Center · Oklahoma City
- Texas Oncology - Gulf Coast · The Woodlands
- Virginia Oncology Associates · Norfolk
- University of Washington - Seattle Cancer Care Alliance · Seattle
- Cabrini Hospital · Malvern
- Princess Margaret Cancer Center · Toronto
- McGill University Health Centre - Glen Site · Montreal
- Gynekologicko-porodnicka klinika · Prague
- CHU Besançon - Hôpital Jean Minjoz · Besançon
- Centre Francois Baclesse · Caen
- Centre Leon Berard · Lyon
- Groupe Hospitalier Diaconesses · Paris
- Centre Eugène Marquis · Rennes
- ICO - Site René Gauducheau · Saint-Herblain
- Institut Claudius Regaud · Toulouse
- Gustave Roussy · Villejuif
- Kliniken Essen-Mitte Evang. Huyssens-Stiftung, Klinik für Gynäkologie und gynäkologische Onkologie · Essen
- Universitätsklinikum Mannheim · Mannheim
- A.O. U. Consorziale Policlinico di Bari · Bari
- Istituto Tumori Napoli · Naples
- Policlinico Universitario Agostino Gemelli · Rome
- IRCCS S. Raffaele · Milan
- LLC Medscan · Moskva
- Samsung Medical Center · Seoul
- Seoul National University Hospital · Seoul
- Severance Hospital, Yonsei University Health System · Seoul
公开的入选条件
- * Persistent or recurrent EOC that meets the following criteria: Histologically confirmed non-high-grade serous, non-high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer, including but not limited to low-grade serous ovarian
- * Measurable disease (at least one target lesion) according to RECIST v1.1
- * Previous treatment with one to four lines of therapy, at least one of which was platinum-based. Hormonal therapy does not count as a line of therapy.
- * Platinum-resistant disease, defined as disease progression during or within 6 months of last platinum therapy, with the following exception: Participants with primary platinum-refractory disease are excluded.
- * Submission of a representative tumor specimen that is suitable for next-generation sequencing (NGS) testing and estrogen receptor immunohistochemistry (ER IHC) to determine treatment arm assignment and for central pathology review.
- * Submission of the local pathology report and, if available, any associated stained slides that supported the local diagnosis of the histology (to be used for central pathology review)
- * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- * Adequate hematologic and end-organ function
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04931342；登记信息更新于 2026-09-10。